Cargando…

Validation of the Model of End-Stage Liver Disease for Liver Transplant Allocation in Alberta: Implications for Future Directions in Canada

Background. Since 2002, the Model of End-Stage Liver Disease (MELD) has been used for allocation of liver transplants (LT) in the USA. In Canada, livers were allocated by the CanWAIT algorithm. The aim of this study was to compare the abilities of MELD, Child-Pugh (CP), and CanWAIT status to predict...

Descripción completa

Detalles Bibliográficos
Autores principales: Burak, Kelly W., Meeberg, Glenda A., Myers, Robert P., Fick, Gordon H., Swain, Mark G., Bain, Vincent G., Kneteman, Norman M., Hilsden, Robert J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4904690/
https://www.ncbi.nlm.nih.gov/pubmed/27446823
http://dx.doi.org/10.1155/2016/1329532
_version_ 1782437188167794688
author Burak, Kelly W.
Meeberg, Glenda A.
Myers, Robert P.
Fick, Gordon H.
Swain, Mark G.
Bain, Vincent G.
Kneteman, Norman M.
Hilsden, Robert J.
author_facet Burak, Kelly W.
Meeberg, Glenda A.
Myers, Robert P.
Fick, Gordon H.
Swain, Mark G.
Bain, Vincent G.
Kneteman, Norman M.
Hilsden, Robert J.
author_sort Burak, Kelly W.
collection PubMed
description Background. Since 2002, the Model of End-Stage Liver Disease (MELD) has been used for allocation of liver transplants (LT) in the USA. In Canada, livers were allocated by the CanWAIT algorithm. The aim of this study was to compare the abilities of MELD, Child-Pugh (CP), and CanWAIT status to predict 3-month and 1-year mortality before LT in Canadian patients and to describe the use of MELD in Canada. Methods. Validation of MELD was performed in 320 patients listed for LT in Alberta (1998–2002). In October 2014, a survey of MELD use by Canadian LT centers was conducted. Results. Within 1 year of listing, 47 patients were removed from the waiting list (29 deaths, 18 too ill for LT). Using logistic regression, the MELD and CP were better than the CanWAIT at predicting 3-month (AUROC: 0.79, 0.78, and 0.59; p = 0.0002) and 1-year waitlist mortality (AUROC: 0.70, 0.70, and 0.55; p = 0.0023). Beginning in 2004, MELD began to be adopted by Canadian LT programs but its use was not standardized. Conclusions. Compared with the CanWAIT system, the MELD score was significantly better at predicting LT waitlist mortality. MELD-sodium (MELD-Na) has now been adopted for LT allocation in Canada.
format Online
Article
Text
id pubmed-4904690
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-49046902016-06-30 Validation of the Model of End-Stage Liver Disease for Liver Transplant Allocation in Alberta: Implications for Future Directions in Canada Burak, Kelly W. Meeberg, Glenda A. Myers, Robert P. Fick, Gordon H. Swain, Mark G. Bain, Vincent G. Kneteman, Norman M. Hilsden, Robert J. Can J Gastroenterol Hepatol Research Article Background. Since 2002, the Model of End-Stage Liver Disease (MELD) has been used for allocation of liver transplants (LT) in the USA. In Canada, livers were allocated by the CanWAIT algorithm. The aim of this study was to compare the abilities of MELD, Child-Pugh (CP), and CanWAIT status to predict 3-month and 1-year mortality before LT in Canadian patients and to describe the use of MELD in Canada. Methods. Validation of MELD was performed in 320 patients listed for LT in Alberta (1998–2002). In October 2014, a survey of MELD use by Canadian LT centers was conducted. Results. Within 1 year of listing, 47 patients were removed from the waiting list (29 deaths, 18 too ill for LT). Using logistic regression, the MELD and CP were better than the CanWAIT at predicting 3-month (AUROC: 0.79, 0.78, and 0.59; p = 0.0002) and 1-year waitlist mortality (AUROC: 0.70, 0.70, and 0.55; p = 0.0023). Beginning in 2004, MELD began to be adopted by Canadian LT programs but its use was not standardized. Conclusions. Compared with the CanWAIT system, the MELD score was significantly better at predicting LT waitlist mortality. MELD-sodium (MELD-Na) has now been adopted for LT allocation in Canada. Hindawi Publishing Corporation 2016 2016-04-03 /pmc/articles/PMC4904690/ /pubmed/27446823 http://dx.doi.org/10.1155/2016/1329532 Text en Copyright © 2016 Kelly W. Burak et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Burak, Kelly W.
Meeberg, Glenda A.
Myers, Robert P.
Fick, Gordon H.
Swain, Mark G.
Bain, Vincent G.
Kneteman, Norman M.
Hilsden, Robert J.
Validation of the Model of End-Stage Liver Disease for Liver Transplant Allocation in Alberta: Implications for Future Directions in Canada
title Validation of the Model of End-Stage Liver Disease for Liver Transplant Allocation in Alberta: Implications for Future Directions in Canada
title_full Validation of the Model of End-Stage Liver Disease for Liver Transplant Allocation in Alberta: Implications for Future Directions in Canada
title_fullStr Validation of the Model of End-Stage Liver Disease for Liver Transplant Allocation in Alberta: Implications for Future Directions in Canada
title_full_unstemmed Validation of the Model of End-Stage Liver Disease for Liver Transplant Allocation in Alberta: Implications for Future Directions in Canada
title_short Validation of the Model of End-Stage Liver Disease for Liver Transplant Allocation in Alberta: Implications for Future Directions in Canada
title_sort validation of the model of end-stage liver disease for liver transplant allocation in alberta: implications for future directions in canada
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4904690/
https://www.ncbi.nlm.nih.gov/pubmed/27446823
http://dx.doi.org/10.1155/2016/1329532
work_keys_str_mv AT burakkellyw validationofthemodelofendstageliverdiseaseforlivertransplantallocationinalbertaimplicationsforfuturedirectionsincanada
AT meebergglendaa validationofthemodelofendstageliverdiseaseforlivertransplantallocationinalbertaimplicationsforfuturedirectionsincanada
AT myersrobertp validationofthemodelofendstageliverdiseaseforlivertransplantallocationinalbertaimplicationsforfuturedirectionsincanada
AT fickgordonh validationofthemodelofendstageliverdiseaseforlivertransplantallocationinalbertaimplicationsforfuturedirectionsincanada
AT swainmarkg validationofthemodelofendstageliverdiseaseforlivertransplantallocationinalbertaimplicationsforfuturedirectionsincanada
AT bainvincentg validationofthemodelofendstageliverdiseaseforlivertransplantallocationinalbertaimplicationsforfuturedirectionsincanada
AT knetemannormanm validationofthemodelofendstageliverdiseaseforlivertransplantallocationinalbertaimplicationsforfuturedirectionsincanada
AT hilsdenrobertj validationofthemodelofendstageliverdiseaseforlivertransplantallocationinalbertaimplicationsforfuturedirectionsincanada